Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
BCRX Stock Chart & Stats
$7.13
-$0.02(-0.25%)
At close: 4:00 PM EST
$7.13
-$0.02(-0.25%)
Day’s Range― - ―
52-Week Range$6.00 - $11.31
Previous CloseN/A
Volume537.69K
Average Volume (3M)4.12M
Market Cap
$1.57B
Enterprise Value$2.14B
Total Cash (Recent Filing)$212.87M
Total Debt (Recent Filing)$683.11M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Feb 25, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding210,543,230
10 Day Avg. Volume4,370,675
30 Day Avg. Volume4,116,436
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)-3.27
Price to Sales (P/S)3.45
P/FCF Ratio-29.25
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue3.57
Enterprise Value/Gross Profit3.66
Enterprise Value/Ebitda25.50
Forecast
1Y Price Target
$19.45Price Target Upside172.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.12
Revenue Forecast (FY)$619.06M
Bulls Say, Bears Say
Bulls Say
Innovative Drug FormulationBioCryst Pharmaceuticals announced the approval of a granule formulation of Orladeyo for the prophylactic treatment of hereditary angioedema in pediatric patients.
Pediatric Market ExpansionBCRX's expanding presence in the prophylactic HAE treatment space will provide both near-term and long-term revenue growth, while also providing insulation against future competition.
Strategic Drug DevelopmentAdding navenibart to the model supports a price target increase, showing confidence in its potential market impact.
Bears Say
Competitive Market ConcernsCurrent stock reactions reflect competitive fears and controversy on peak sales for both Orladeyo and navenibart.
Delayed Clinical DataMgmt now guides to initial Netherton data in 1Q26 instead of year-end, indicating a delay.
Sales Decline ProjectionA slight Q/Q tickdown in Orladeyo sales is expected in 4Q25 to reflect the sale divestment of its EU business.
BioCryst News
BCRX FAQ
What was Biocryst Pharmaceuticals’s price range in the past 12 months?
Biocryst Pharmaceuticals lowest stock price was $6.00 and its highest was $11.31 in the past 12 months.
What is Biocryst Pharmaceuticals’s market cap?
Biocryst Pharmaceuticals’s market cap is $1.57B.
When is Biocryst Pharmaceuticals’s upcoming earnings report date?
Biocryst Pharmaceuticals’s upcoming earnings report date is Feb 25, 2026 which is in 69 days.
How were Biocryst Pharmaceuticals’s earnings last quarter?
Biocryst Pharmaceuticals released its earnings results on Nov 03, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02.
Is Biocryst Pharmaceuticals overvalued?
According to Wall Street analysts Biocryst Pharmaceuticals’s price is currently Undervalued.
Does Biocryst Pharmaceuticals pay dividends?
Biocryst Pharmaceuticals does not currently pay dividends.
What is Biocryst Pharmaceuticals’s EPS estimate?
Biocryst Pharmaceuticals’s EPS estimate is 0.03.
How many shares outstanding does Biocryst Pharmaceuticals have?
Biocryst Pharmaceuticals has 210,543,230 shares outstanding.
What happened to Biocryst Pharmaceuticals’s price movement after its last earnings report?
Biocryst Pharmaceuticals reported an EPS of $0.06 in its last earnings report, beating expectations of $0.04. Following the earnings report the stock price went down -6.284%.
Which hedge fund is a major shareholder of Biocryst Pharmaceuticals?
Currently, no hedge funds are holding shares in BCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioCryst Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.45 (172.79% Upside)
$19.45 (172.79% Upside)
Blogger Sentiment
Bullish
BCRX Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 7.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $367.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.13%
Trailing 12-Months
Company Description
Biocryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on the development and commercialization of innovative therapies for rare diseases. The company specializes in the design and development of small molecule drugs that target specific enzymes, particularly in the field of hereditary angioedema (HAE) and other rare diseases. BioCryst's core products include ORLADEYO (berotralstat), an oral medication approved for the prevention of HAE attacks, as well as a pipeline of other drug candidates aimed at treating various rare conditions.
BCRX Company Deck
BCRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflected a strong performance by BioCryst with significant revenue growth, successful financial maneuvers, and promising pipeline developments. However, there were some challenges, including enrollment delays and increased costs. Overall, the company's positive results and strategic decisions indicate a promising outlook.View all BCRX earnings summariesBCRX Stock 12 Month Forecast
Average Price Target
$19.45
▲(172.79% Upside)
Technical Analysis
Vericel
―
Celldex
―
Sarepta Therapeutics
―
Aurinia Pharmaceuticals
―
Cidara Therapeutics
―
Ownership Overview
1.73% Insiders
17.54% Mutual Funds
28.29% Other Institutional Investors
34.12% Public Companies and Individual Investors